4 results
The primary objective is:* To determine the overall response rate (ORR) of 4 weekly infusions of obinutuzumab monotherapy (Induction I) in patients with rituximab-refractory follicular lymphoma.The secondary objectives are:* To determine the…
The primary outcome of the study is a 50% reduction in exacerbation rate in patients using TIS once daily (OD). Secondary outcome parameters are lung function (FEV1, FVC), QoL (QOL-B), LTRI-VAS, Leicester cough score), bacterial load in sputum and…
Primary ObjectivesPhase 1bConfirm the recommended CyPep-1 dose 20 mg every two weeks (Q2W) when administered by intratumoral (IT) injection in combination with pembrolizumab Phase 2aAssess the anti-tumor activity of CyPep-1 administered by IT…
The primary objective of this study is to investigate the potential differential effects of RTX and OBI on the composition of lymph nodes and other target organs (i.e. skin and/or kidney) as well as (subsets of) immune cells in the peripheral blood…